biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > APOSENSE PATENT ISSUANCE LAST WEEK

<< Previous

Bullboard Posts

Next >>

Comment by JDavenporton Apr 07, 2022 7:42pm

108 Views

Post# 34586333

RE:APOSENSE PATENT ISSUANCE LAST WEEK

If you go << here >> you'll find that delivery across the BBB is referenced. The patent contain no reference to LRP-1, Bioasis, xB3 or "receptor," as in receptor mediated transcytosis.

The other one doesn't reference the BBB at all.

jd

I apologize for typos in my previous post, and in every post I've ever put on here.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages